ALMR · Alamar Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · ALMR
Income Statement
| Line item | Q1 '26 |
|---|---|
| Revenue | $13.09M |
| Cost of Revenue | $6.70M |
| Gross Profit | $6.39M |
| R&D | $8.30M |
| SG&A | $6.64M |
| Total Operating Expenses | $14.94M |
| D&A | $888.0K |
| Operating Income | ($8.55M) |
| Interest Expense | - |
| Income Tax | $464.0K |
| Net Income | ($7.66M) |
| EPS - Basic | ($0.68) |
| EPS - Diluted | ($0.68) |
Balance Sheet
| Line item | Q1 '26 |
|---|---|
| Cash & Equivalents | $30.00M |
| Accounts Receivable | $12.75M |
| Inventory | $38.48M |
| Accounts Payable | $5.87M |
| Current Assets | $94.70M |
| Total Assets | $139.99M |
| Current Liabilities | $23.73M |
| Long-term Debt | - |
| Total Liabilities | $63.95M |
| Stockholders' Equity | ($158.95M) |
| Retained Earnings | ($168.78M) |
Cash Flow
| Line item | Q1 '26 |
|---|---|
| Operating Cash Flow | ($13.07M) |
| Investing Cash Flow | $17.02M |
| Financing Cash Flow | $243.0K |
| CapEx | $554.0K |
| Free Cash Flow | ($13.62M) |
Ratios
| Metric | Q1 '26 |
|---|---|
| Profitability | |
| Gross margin | 48.8% |
| Operating margin | -65.3% |
| EBITDA margin | -58.6% |
| Net margin | -58.5% |
| Free cash flow margin | -104.1% |
| FCF / Net income | 1.78 |
| R&D / Revenue | 63.4% |
| SG&A / Revenue | 50.7% |
| Effective tax rate | - |
| Return on assets | -5.5% |
| Return on equity | 4.8% |
| Return on invested capital | - |
| Liquidity | |
| Current ratio | 3.99 |
| Quick ratio | 2.37 |
| Cash ratio | 1.26 |
| Leverage | |
| Debt / Equity | - |
| Debt / Assets | - |
| Debt / EBITDA | - |
| Interest coverage | - |
| Equity multiplier | -0.88 |
| Liabilities / Assets | 0.46 |
| Efficiency | |
| Asset turnover | 0.09 |
| Inventory turnover | 0.17 |
| Days sales outstanding | 356d |
| Days inventory outstanding | 2096d |
| Days payable outstanding | 320d |
| Cash conversion cycle | 2132d |
| Valuation | |
| P / E | - |
| P / B | - |
| P / S | - |
| EV / EBITDA | - |
| Growth | |
| Revenue growth (YoY) | - |
| Revenue CAGR (3y) | - |
| Revenue CAGR (5y) | - |
| Gross profit growth (YoY) | - |
| Operating income growth (YoY) | - |
| Net income growth (YoY) | - |
| EPS growth (YoY) | - |
| EPS CAGR (3y) | - |
| EPS CAGR (5y) | - |
| FCF growth (YoY) | - |
| FCF CAGR (5y) | - |
| Book value growth (YoY) | - |
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Alamar Biosciences against the 5 most active filers in the same SIC group.